BRAF and melanoma: In 2014, nivolumab was approved as second-line therapy among patients with disease refractory to ipilimumab or a BRAF inhibitor for advanced melanoma after the positive results of the CheckMate 037 trial based on higher rates of response compared with the investigator’s choice of chemotherapy (ie, 32% vs 11%).29,30 The updated analysis published later does not show overall survival benefit.29,30